<DOC>
	<DOCNO>NCT01817530</DOCNO>
	<brief_summary>This Phase 2b randomize , double-blind , placebo-controlled study evaluate safety efficacy elagolix alone combination add-back therapy versus placebo heavy menstrual bleeding premenopausal woman 18 51 year age uterine fibroid .</brief_summary>
	<brief_title>Safety Efficacy Premenopausal Women With Heavy Menstrual Bleeding ( HMB ) Associated With Uterine Fibroids ( UF )</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Subject premenopausal female 18 51 year age Screening . Subject diagnosis uterine fibroid document Pelvic Ultrasound . Subject heavy uterine bleeding associate uterine fibroid . Exclusion Criteria : Subject myomectomy , uterine artery embolization high intensity focus ultrasound fibroid destruction within 6 month prior Screening endometrial ablation within 5 year prior Screening . Subject history osteoporosis metabolic bone disease . Subject show evidence clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric ( include depression , schizophrenia , bipolar disorder ) , neurologic disease uncontrolled medical illness uncontrolled type 2 diabetes . Subject history attempt suicide . Subject history clinically significant condition ( ) include limited : * Symptomatic Endometriosis * Epilepsy seizures * Type 1 diabetes * Chronic kidney disease * Any cancer ( except treat basal cell carcinoma skin ) , include breast ovarian cancer subject take systemic cancer chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Uterine Fibroids</keyword>
	<keyword>Leiomyomata</keyword>
	<keyword>Elagolix</keyword>
	<keyword>Menorrhagia</keyword>
	<keyword>Elagolix sodium</keyword>
	<keyword>Heavy Uterine Bleeding</keyword>
	<keyword>ABT-620</keyword>
</DOC>